Two Sigma Advisers LP Sells 41,858 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Two Sigma Advisers LP decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 88.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,400 shares of the biotechnology company's stock after selling 41,858 shares during the period. Two Sigma Advisers LP's holdings in Ascendis Pharma A/S were worth $743,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Blue Trust Inc. boosted its holdings in Ascendis Pharma A/S by 540.5% in the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock worth $76,000 after buying an additional 427 shares during the last quarter. abrdn plc lifted its position in shares of Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after acquiring an additional 28,967 shares in the last quarter. Legato Capital Management LLC boosted its stake in shares of Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock worth $264,000 after acquiring an additional 134 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $203,000. Finally, Rice Hall James & Associates LLC increased its position in shares of Ascendis Pharma A/S by 2.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock worth $22,562,000 after purchasing an additional 3,274 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ASND shares. Bank of America raised their target price on Ascendis Pharma A/S from $196.00 to $201.00 and gave the stock a "buy" rating in a research note on Tuesday. Royal Bank of Canada raised their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and set a $200.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Finally, The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $216.73.

Ascendis Pharma A/S Stock Up 1.1%

NASDAQ:ASND traded up $1.94 on Thursday, reaching $175.63. The stock had a trading volume of 219,855 shares, compared to its average volume of 489,282. The stock has a fifty day moving average price of $158.09 and a 200-day moving average price of $145.77. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00. The company has a market capitalization of $10.71 billion, a P/E ratio of -24.73 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.